SCHEMBL15564633

SCHEMBL15564633

CC(=O)Nc1c(O)nc(C)nc1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.37
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
PKM P14618 1/20 0.36
ALDH1A1 P00352 4/20 0.35
MAPT P10636 2/20 0.35
TSHR P16473 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
LMNA P02545 1/20 0.35
MEN1 O00255 1/20 0.35
CA12 O43570 1/20 0.35
BRD4 O60885 1/20 0.35
NR1I2 O75469 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
MB P02144 1/20 0.35
CYP1A1 P04798 1/20 0.35
CA3 P07451 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5774866 0.90 KMT2A (0.39) KMT2AL3MBTL1POLBGAAPKM
SCHEMBL11015282 0.86 KMT2A (0.37) KMT2AL3MBTL1POLBGAAPKM
SCHEMBL7756861 0.80 KMT2A (0.41) KMT2APOLBGAAALDH1A1MAPT
SCHEMBL15565552 0.80 KMT2A (0.41) KMT2AL3MBTL1POLBALDH1A1MAPT
SCHEMBL15564197 0.73 L3MBTL1 (0.54) KMT2AL3MBTL1POLBGAAPKM
SCHEMBL12766932 0.71 POLB (0.54) L3MBTL1POLBALDH1A1MAPTCYP1A2
SCHEMBL3804852 0.71 KMT2A (0.38) KMT2APOLBGAAALDH1A1MAPT
SCHEMBL11131428 0.71 ALDH1A1 (0.37) L3MBTL1GAAPKMALDH1A1MAPT
SCHEMBL15565380 0.70 ALPL (0.55) KMT2APOLBALDH1A1MAPTLMNA
SCHEMBL19512658 0.70 CYP1A2 (0.44) L3MBTL1POLBGAAPKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2882720-A1 A PROCESS FOR THE PREPARATION OF AN INTERMEDIATE FOR A TRIAZOLOPYRIMIDINE CARBONUCLEOSIDE Enantia, S.L. (ES) 2015-06-17 EP disclosed
US-20150152114-A1 PROCESS FOR THE PREPARATION OF AN INTERMEDIATE FOR A TRIAZOLOPYRIMIDINE CARBONUCLEOSIDE ENANTIA, S.L. (ES) 2015-06-04 US disclosed
US-20150152114-A1 PROCESS FOR THE PREPARATION OF AN INTERMEDIATE FOR A TRIAZOLOPYRIMIDINE CARBONUCLEOSIDE ENANTIA, S.L. (ES) 2015-06-04 US disclosed
US-20150152114-A1 PROCESS FOR THE PREPARATION OF AN INTERMEDIATE FOR A TRIAZOLOPYRIMIDINE CARBONUCLEOSIDE ENANTIA, S.L. (ES) 2015-06-04 US disclosed
WO-2014023681-A1 A PROCESS FOR THE PREPARATION OF AN INTERMEDIATE FOR A TRIAZOLOPYRIMIDINE CARBONUCLEOSIDE ENANTIA, S.L. (ES) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152114-A1 PROCESS FOR THE PREPARATION OF AN INTERMEDIATE FOR A TRIAZOLOPYRIMIDINE CARBONUCLEOSIDE NUDT1, DUT, UMPS KMT2A 2681/4885L3MBTL1 4741/4885POLB 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.